Collection 2 (Sep 2021 - Aug 2022) Articles

Articles
Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
Bajaj A, Cuchel M
Journal:
J Atheroscler Thromb

First published: April 24, 2022 DOI: 10.5551/jat.RV17065
View
- Share
Articles
Alirocumab after acute coronary syndrome in patients with a history of heart failure
White HD, Schwartz GG, Szarek M, et al.
Journal:
Eur Heart J

First published: April 21, 2022 DOI: 10.1093/eurheartj/ehab804
View
- Share
Articles
Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis
Wang N, Woodward M, Huffman MD, et al.
Journal:
Circ Cardiovasc Qual Outcomes

First published: April 18, 2022 DOI: 10.1161/CIRCOUTCOMES.121.008552
View
- Share
Articles
Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study
Vasan RS, Enserro DM, Xanthakis V, et al.
Journal:
Circulation

First published: April 18, 2022 DOI: 10.1161/CIRCULATIONAHA.121.057889
View
- Share
Articles
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
Toscano A, Cinquegrani M, Scuruchi M, et al.
Journal:
Biomolecules

First published: April 9, 2022 DOI: 10.3390/biom12040562
View
- Share
Articles
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial
Räber L, Ueki Y, Otsuka T, et al.
Journal:
JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5218
View
- Share
Articles
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70
Bergmark BA, Marston NA, Bramson CR, et al.
Journal:
Circulation

First published: April 3, 2022 DOI: 10.1161/CIRCULATIONAHA.122.059266
View
- Share
Articles
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels
Nissen SE, Wolski K, Balog C, et al.
Journal:
JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5050
View
- Share
Articles
The Potential Clinical Benefit of Lowering Lipoprotein(a)
Ference BA
Journal:
JAMA

First published: April 3, 2022 DOI: 10.1001/jama.2022.5333
View
- Share
Articles
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
Ostadal P, Steg PG, Poulouin Y, et al.
Journal:
Lancet Diabetes Endocrinol

First published: April 1, 2022 DOI: 10.1016/S2213-8587(22)00043-2
View
- Share
Articles
Big Data and ASCVD Risk Prediction: Building a Better Mouse Trap?
Nasir K, DeFilippis A
Journal:
J Am Coll Cardiol

First published: March 29, 2022 DOI: 10.1016/j.jacc.2022.01.020
View
- Share
Articles
Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia
Hovingh GK, Klausen IC, Heggen E, et al
Journal:
J Am Coll Cardiol

First published: March 29, 2022 DOI: 10.1016/j.jacc.2022.01.023
View
- Share

1 … 4 5 6 7 8 … 14

Collection 2 (Sep 2021 - Aug 2022) Articles

Articles

Advancements in the Treatment of Homozygous Familial Hypercholesterolemia

Bajaj A, Cuchel M

Articles

Alirocumab after acute coronary syndrome in patients with a history of heart failure

White HD, Schwartz GG, Szarek M, et al.

Articles

Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis

Wang N, Woodward M, Huffman MD, et al.

Articles

Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study

Vasan RS, Enserro DM, Xanthakis V, et al.

Articles

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Toscano A, Cinquegrani M, Scuruchi M, et al.

Articles

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial

Räber L, Ueki Y, Otsuka T, et al.

Articles

Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Bergmark BA, Marston NA, Bramson CR, et al.

Articles

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels

Nissen SE, Wolski K, Balog C, et al.

Articles

The Potential Clinical Benefit of Lowering Lipoprotein(a)

Ference BA

Articles

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ostadal P, Steg PG, Poulouin Y, et al.

Articles

Big Data and ASCVD Risk Prediction: Building a Better Mouse Trap?

Nasir K, DeFilippis A

Articles

Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia

Hovingh GK, Klausen IC, Heggen E, et al

Articles

Advancements in the Treatment of Homozygous Familial Hypercholesterolemia

Bajaj A, Cuchel M

Share

Articles

Alirocumab after acute coronary syndrome in patients with a history of heart failure

White HD, Schwartz GG, Szarek M, et al.

Share

Articles

Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis

Wang N, Woodward M, Huffman MD, et al.

Share

Articles

Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study

Vasan RS, Enserro DM, Xanthakis V, et al.

Share

Articles

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Toscano A, Cinquegrani M, Scuruchi M, et al.

Share

Articles

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial

Räber L, Ueki Y, Otsuka T, et al.

Share

Articles

Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Bergmark BA, Marston NA, Bramson CR, et al.

Share

Articles

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels

Nissen SE, Wolski K, Balog C, et al.

Share

Articles

The Potential Clinical Benefit of Lowering Lipoprotein(a)

Ference BA

Share

Articles

Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ostadal P, Steg PG, Poulouin Y, et al.

Share

Articles

Big Data and ASCVD Risk Prediction: Building a Better Mouse Trap?

Nasir K, DeFilippis A

Share

Articles

Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia

Hovingh GK, Klausen IC, Heggen E, et al

Share